#########
Volume 11, Number 13
Monday, March 28, 2011
#########

In this issue: (click heading to view article)
#########
######### Impact of Dietary Omega-3 Fatty Acid and Fish Intake on AMD Incidence

#########
######### Corneal Transplantation in Infants, Children and Adolescents
#########
######### Incidence of Endophthalmitis Following Pars Plana Vitrectomy
#########
######### Conformation and Thermodynamic Changes of MGD
#########
######### Briefly

 

Impact of Dietary Omega-3 Fatty Acid and Fish Intake on AMD Incidence

A detailed food-frequency questionnaire was administered at baseline among 39,876 female health professionals (mean [SD] age: 54.6 [7.0] years) to examine whether intake of –3 fatty acids and fish affects incidence of age-related macular degeneration (AMD) in women.

It was reported that 38,022 women completed the questionnaire and were free of a diagnosis of AMD. The main outcome measure was incident AMD responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.

During an average of 10 years of follow up, 235 cases of AMD, most characterized by some combination of drusen and retinal pigment epithelial (RPE) changes, were confirmed. It was noted that women in the highest tertile of intake for docosahexaenoic acid, compared with those in the lowest, had a multivariate-adjusted relative risk of AMD of 0.62 (95% confidence interval, 0.44–0.87). For eicosapentaenoic acid, women in the highest tertile of intake had a relative risk of 0.66 (95% confidence interval, 0.48–0.92). Consistent with the findings for docosahexaenoic acid and eicosapentaenoic acid, women who consumed 1 or more servings of fish per week, compared with those who consumed less than 1 serving per month, had a relative risk of AMD of 0.58 (95% confidence interval, 0.38–0.87).

In conclusion, these prospective data from a large cohort of female health professionals without a diagnosis of AMD at baseline indicate that regular consumption of docosahexaenoic acid and eicosapentaenoic acid and fish was associated with a significantly decreased risk of incident AMD and may be of benefit in primary prevention of AMD.

SOURCE: Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary omega-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol. 2011; March 14 [Epub ahead of print].

http://www.haag-streit-brands.com/products/octopus/game-over/







Corneal Transplantation in Infants, Children and Adolescents

The authors of this large, prospective cohort study examined factors affecting penetrating corneal graft survival and visual outcomes in patients aged less than 20 years and found that corneal grafts for keratoconus in adolescents show excellent survival.

They searched the records of 14,865 followed penetrating corneal grafts in 11,929 patients to identify 765 grafts in 640 patients aged younger than 20 years of age at the time of graft. Using Kaplan-Meier survival plots and Cox proportional hazards regression analysis, they analyzed records submitted to the Australian Corneal Graft Registry by 381 ophthalmic surgeons and 253 follow-up practitioners from May 1985 to June 2009. Probability of corneal graft survival and Snellen acuity at the time of most recent follow up and at defined intervals post-graft were the main outcome measures.

According to the study authors, infants (<5 years) exhibited poorer graft survival than children aged 5 to 12 years and adolescents (13–19 years) exhibited better corneal graft survival than other age groups; 86% of grafts in adolescents were for keratoconus. They reported that factors significantly affecting corneal graft survival in pediatric patients included indication for graft, graft inflammation, history of intraocular surgery, vascularization, rejection episodes, post-graft operative procedures and refractive surgery. The authors also found that 14% of pediatric grafts failed, of which 65% failed within 2 years post-graft and that 44% of failures were due to unknown causes (18) or irreversible rejection (30).

They determined that infants exhibit poor graft survival and visual outcomes, especially those undergoing transplantation for Peters' anomaly and that corneal graft survival and visual outcomes vary more by indication for graft than recipient age. The major reason for graft failure is irreversible rejection. Corneal transplantation improves overall bilateral vision in pediatric patients.


SOURCE: Lower MT, Keane MC, Coster DJ, Williams KA. The outcome of corneal transplantation in infants, children, and adolescents. Ophthalmology. 2011;118(3);492–497.






Incidence of Endophthalmitis Following Pars Plana Vitrectomy

To determine the incidence of endophathlmitis after 20-, 23- and 25-gauge pars plana vitrectomies (PPVs), investigators conducted a retrospective comparative case series of consecutive patients at 11 centers from Latin America during the years 2005 to 2009.

They identified PPV cases through a search of the billing records of each institution and excluded cases of PPV performed in the management of trauma, endophthalmitis and combined PPV phacoemulsification cases. The study investigators diagnosed endophthalmitis by clinical criteria regardless of the microbiologic results and compared the incidence of post-PPV endophthalmitis between 20-, 23- and 25-gauge PPVs.

They identified 35,427 cases of PPV during the study period (n=19,865 for 20 gauge, n=10,845 for 23 gauge and n=4,717 for 25 gauge). They reported that the 5-year post-PPV endophthalmitis incidence rates were 0.020% (4 of 19,865), 0.028% (3 of 10,845) and 0.021% (1 of 4,717) for 20 gauge, 23 gauge and 25 gauge, respectively (p=0.9685).

To conclude, small-gauge transconjunctival PPV does not appear to increase the rates of post-PPV endophthalmitis.

SOURCE: Wu L, Berrocal MH, Arévalo JF, et al. Endophthalmitis after pars plana vitrectomy: results of the Pan American Collaborative Retina Study Group. Retina. 2011; March 9 [Epub ahead of print].







Conformation and Thermodynamic Changes of MGD

Instability of the tear film with rapid tear break-up time is a common feature of aqueous deficient and evaporative dry eye diseases, suggesting there may be a shared structural abnormality of the tear film that is responsible for the instability. A change in the normal meibum lipid composition and conformation is possibly this event. Principle Component Analysis of infrared spectra of human meibum indicate that human meibum collected from normal donors (Mn) is more ordered than meibum from donors with meibomian gland dysfunction (Md). In this study, researchers at the University of Louisville in Kentucky quantified the conformation of Md to test this finding.

They measured changes in lipid conformation with temperature using infrared spectroscopy. There were two phases to the study. In phase 1, the researchers measured the phase transitions of human samples, Mn and Md and in phase 2, they measured phase transitions of model lipid standards composed of different waxes and cholesterol ester.

They found that the phase transition temperature was significantly higher by 4°C for Md compared to Mn of age-matched donors with no history of dry-eye symptoms and that most (82%) of the phase-transition temperatures measured for Md were above the values for Mn. According to the researchers, the small change in the transition temperature was amplified in the average lipid order (stiffness) at 33.4°C and the average lipid order at 33.4°C for Md was significantly higher (30%, p=0.004), than for Mn. They also noted that the strength of lipid-lipid interactions was 72% higher for Md compared to Mn. The ability of one lipid to influence the melting of adjacent lipids is termed cooperativity. The researchers found no significant differences between Mn and Md in the phase transition cooperativity, nor was there a difference between Mn and Md in the minimum order or maximum order that Mn and Md can achieve at very low and very high temperatures, respectively. From their model wax studies, the researchers found that the phase transition of complex mixtures of natural lipids is “set” by the level of unsaturation. They observed that the double bond decreased the phase transition temperature by about 40°C and that the addition of a second CH=CH moiety decreased the phase transition temperature by about 19°C. Unsaturated waxes were miscible with saturated waxes and when a saturated wax was mixed with an unsaturated one, the saturated wax disproportionately increased the phase transition of the mixture by about 30°C compared to the saturated wax alone. Moreover, cholesterol ester had little affect on the phase transition temperature of waxes. Model studies indicate that changes in the amount of lipid saturation rather than the amount of cholesterol esters could be a factor in the observed conformational changes.

The researchers in this study determined that meibum lipid compositional changes with meibomian gland dysfunction reflect changes in hydrocarbon chain conformation and lipid-lipid interaction strength. Spectroscopic techniques are useful to study the lipid-lipid interactions and conformation of lipid from individual patients.

SOURCE: Borchman D, Foulks GN, Yappert MC, et al. Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction. Invest Ophthalmol Vis Sci. 2011; March 11 [Epub ahead of print].




  • FDA CLEARS LENSAR LASER SYSTEM FOR LENS FRAGMENTATION AND ANTERIOR CAPSULOTOMY IN CATARACT SURGERY. LensAR, Inc. has received 510(k) clearance from the FDA for use of the LensAR Laser System for anterior capsulotomy and lens fragmentation during cataract surgery. According to the company, the proprietary 3D-CSI (Confocal Structured Illumination) imaging and biometry system is being designed to image and analyze the anatomy across all grades of cataract to improve proficiency. The system has been used in more than 500 eyes outside the United States to date. For other indications, it is an investigational device limited by U.S. law to investigational use only. Go LensAR's website for more information.
  • OMEROS'S OMS302 ACHIEVES CO-PRIMARY ENDPOINTS IN PHASE 2B CLINICAL STUDY. Omeros Corporation recently reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. OMS032, added to standard irrigation solution used during ophthalmological procedures, is the company's proprietary PharmacoSurgery product in development to maintain intra-operative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. The multicenter, randomized, double-blind, vehicle-controlled Phase 2b trial included 221 patients treated with OMS302. Subjects demonstrated statistically significant (p<0.0001) and clinically meaningful maintenance of mydriasis throughout the cataract procedure. OMS302 was also significantly decreased (p=0.0418) pain in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients). Additionally, the drug product was safe and well-tolerated in the study.
  • WITH POSITIVE PHASE 2 RESULTS OF PF-04523655 FOR DME, QUARK AIMS TO INITIATE PHASE 2B STUDY. Quark Pharmaceuticals, Inc. has received results from a prospective, randomized Phase 2 trial, the DEGAS study, which evaluated the safety and efficacy of PF=04523655 (RTP801I-14) in patients with diabetic macular edema (DME). The study was designed with a primary endpoint of mean visual acuity improvements over baseline at 24 months and 184 patients were randomly assigned to four treatment groups; three dose levels of PF-04523655 (RTP801I-14) (0.4 mg, 1 mg and 3mg) or laser. Interim results at 12 months showed that there were no drug-related Serious Adverse Events (SAEs) and following 12 months of treatment with PF-04523655 (RTP801I-14), a dose-dependent improvement in visual acuity was observed with the best results achieved at the 3-mg dose level. The study was terminated at 12 months based upon the interim analysis suggesting that higher doses would be necessary to produce a therapeutic effect sufficiently superior to the current standard of care to benefit patients over the long term, given emerging new therapeutic modalities. Based on these results, and in view of a dose-related effect on vision, Quark and Pfizer have mutually agreed that a Phase 2b study will be conducted by Quark at its own expense under a protocol mutually agreed upon by Quark and Pfizer, where Quark will test higher doses of PF-04523655 (RTP801I-14) and determine the optimal dose for pivotal Phase 3 studies. The two companies have also agreed to amend their existing agreement to enable Quark to conduct the Phase 2b study. For more information, visit www.quarkpharma.com.
  • POSITIVE PHASE ½ RESULTS FOR ISV-303 FOR THE REDUCTION OF PAIN AND INFLAMMATION AFTER CATARACT SURGERY. InSite Vision Incorporated has announced top-line results from its recently completed Phase ½ clinical trial of its topical anti-inflammatory product, ISV-303, intended to reduce the pain and inflammation associated with ocular surgery. The randomized, four-arm study compared once- and twice-daily doses of ISV-303 versus Xibrom and DuraSite (vehicle), each administered twice daily. (ISV-303 combines a lower dose [0.075%] of the non-steroidal anti-inflammatory [NSAID] bromfenac [Bromday/Xibrom (bromfenac ophthalmic solution)] 0.09%, marketed by ISTA Pharmaceuticals) with InSite Vision's proprietary DuraSite drug delivery technology. The Phase ½ clinical trial enrolled 169 patients undergoing cataract surgery. The primary endpoint of the study was the absence of cells in the anterior chamber of the eye at day 15 following surgery. According to InSite, once-daily ISV-303 achieved statistically significant superiority compared to vehicle (53.3% vs. 19.0%, p=0.0016) for the primary endpoint. Click here for more study results. InSite also plans to conduct a Phase 2 pharmacokinetic study of once-daily ISV-303 against ISTA Pharmaceutical's currently marketed once-daily NSAID, Bromday.
  • R-TECH UENO AND SUCAMPO ENTER LICENSE AGREEMENT FOR UNOPROSTONE. After the termination of a license agreement with Novartis Pharma AG last year, R-Tech Ueno, Ltd. sought a new licensee to maximize business profit from unoprostone (Rescula), and has recently signed a new license agreement with Sucampo Manufacturing and Research AG (SMR), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. Under the terms of the agreement, SMR holds exclusive rights to develop, use, make, have made, export, commercialize, promote, offer for sale and sell unoprostone in SMR Territory for its approved indication, the treatment of glaucoma and ocular hypertension. Also under this agreement, SMR has gained the right to develop the drug for additional ophthalmic indications as well as rights to all associated patents and other intellectual property associated with unoprostone in SMR territory. R-Tech Ueno receives an upfront payment of $3 million from SMR upon execution of the agreement and will receive additional milestone payments based on the achievement of specified development and commercialization goals. Read more here.
  • CORRECTION: WAVETEC LAUNCHES ORANGE WAVEFRONT ABERROMETER UPGRADE. Last week, we incorrectly stated that WaveTec Vision will charge practices a flat rate of $30,000 per month for unlimited use of its intraoperative wavefront aberrometer technology. The correct amount is $3,000. Below is the full story with the correction:

    WaveTec Vision has launched its latest system upgrade and has introduced an unlimited-use pricing model for the ORange intraoperative wavefront aberrometer. The company's v2.6 software for ORange includes more than 20 new functions, with special focus on accuracy updates and data sharing. According to WaveTec, improvements to the post-refractive IOL power calculation algorithm and a warning to the user when a measurement is not consistent with the preoperative biometry of the patient are some of the new features. Additionally, moving away from a per-use cost basis, practices will now be charged a flat rate of $3,000 per month for unlimited use of the intraoperative wavefront aberrometer technology. Learn more at www.wavetecvision.com.